Abstract:
La présente invention est relative à un embryon de gallinacé dans lequel des cellules cancéreuses ont été greffées au sein des tissus de l'embryon, caractérisé en ce que l'embryon est à un stade de développement compris entre le stade HH10 et le stade HH25 au moment de la greffe, lesdites cellules cancéreuses n'étant pas des cellules de neuroblastome, et lesdites cellules formant des tumeurs au sein de l'embryon.
Abstract:
Un animal mammifère non humain choisi parmi lapin et porc, porteur d'une tumeur résultant de l'introduction orthotopique de cellules immortalisées, transformées et tumorigènes issues d'un organe d'un animal de la même espèce, lesdites cellules intégrant un ou plusieurs oncogènes, notamment les oncogènes T et t de SV40 et H-Ras V12 . Les cellules peuvent notamment être des hépatocytes ou des cellules du pancréas ou du colon. Procédé de production de ce modèle et utilisation du même pour servir de modèle d'étude permettant de mettre au point des raisonnements diagnostiques, médicaux et/ou chirurgicaux dans le cadre de la prise en charge des cancers.
Abstract:
Provided here are methods for editing of a host genome to knock out or debilitate genes responsible for the growth and/or differentiation of a target organ and injecting that animal at an embryo stage with donor stem cells to complement the missing genetic information for the growth and development of the organ. The result is a chimeric animal in which the complemented tissue (human/humanized organ) matches the genotype and phenotype of the donor. Such organs may be made in a single generation and the stem cell may be taken or generated from the patient's own body. As disclosed herein, it is possible to do so by simultaneously editing multiple genes in a cell or embryo creating a "niche" for the complemented tissue. Multiple genes can be targeted for editing using targeted nucleases and homology directed repair (HDR) templates in vertebrate cells or embryos.
Abstract:
A method of treating an inflammation in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of perforin+ immature DCs (Perf+ im DCs), thereby treating the inflammation in the subject. Methods of generating Perf+ im DCs, wherein the Perf+ im DCs are inhibited from maturing are also disclosed. Isolated population of cells, pharmaceutical compositions and articles of manufacture are also disclosed.
Abstract translation:公开了治疗需要的受试者的炎症的方法。 该方法包括向受试者施用治疗有效量的穿孔素+未成熟DC(Perf + im DC),从而治疗受试者的炎症。 还公开了生成Perf + im DCs的方法,其中Perf + im DC被抑制成熟。 还公开了分离的细胞群,药物组合物和制品。
Abstract:
The invention relates generally to a personalized treatment of a disease or disorder using a humanized non-human mammal model. Specifically, the invention relates to a use of a humanized non-human mammal model for identifying effective therapeutic molecules to provide a personalized treatment of a disease or disorder.
Abstract:
Cell culture systems for producing IL-33 induced T9 cells and methods of using the IL-33 induced T9 cells (T9 IL-33 cells) in a cell therapy for increasing anti-tumoral activity following allogeneic hematopoietic cell transplantation (HCT) and/or treating graft-versus-host disease (GVHD) are disclosed herein. Further, methods of using the T9 IL-33 cells, alone or in combination with allogeneic hematopoietic cell transplantation, are described herein for cancer treatment.
Abstract:
The present disclosure provides a model of human fibrolamellar hepatocellular carcinoma (FL-HCC) cells maintained as a transplantable tumor line in a host and a method to establish a transplantable human FL-HCC tumor line. Methods of ex vivo cultures of the FL-HCC are provided. Methods of diagnosing and treating FL-HCC tumors are also provided.